3-chloro-6-(1H-pyrrol-1-yl)pyr

新型发光试剂ImmunoStar®Zeta的开发

前言 日本和光纯药株式会社于2009年正式将免疫印迹高灵敏度发光试剂ImmunoStar®LD（code NO.290-69904等）投放市场。这种试剂的发光底物，使用了鲁米的诺衍生物L-012（8-Amino-5-chloro-7-phenylpyrido [3,4-d ] pyridazine-1,4-（2H , 3H ） dione Sodium Salt）。L-012与鲁米诺相比，发光信号更强，性能更优异。然而，正因为ImmunoStar®LD与原有的免疫印迹用发光试剂相比

Two‐Step, One‐Pot Synthesis of Inosine, Guanosine, and 2′‐Deoxyguanosine O6‐Ethers via Intermediate O6‐(Benzotriazol‐1‐yl) Derivatives

for the etherification at the O 6 ?position of silyl?protected inosine, guanosine, and 2??deoxyguanosine is described. Typically, a THF solution of the silylated nucleoside is treated with 1H ?benzotriazol?1?yloxy?tris(dimethylamino)phosphonium hexafluorophosphate (BOP

Characterization of Angiotensin II Receptors

1.2 nM [125 I]Ang II working solution (see recipe ) 2 mM 2‐n ‐butyl‐4‐chloro‐5‐(hydroxymethyl)‐1‐{[2′‐(1H ‐tetrazol‐5‐yl) biphenyl‐4‐yl]methyl}‐imidazole (losartan; mol. wt. 461